Mauna Kea Technologies and the American Society for Gastrointestinal Endoscopy Partner in Order to Advance Patient Care and Digestive Health by Promoting Excellence and Innovation in Endoscopy

PARIS--(Marketwire - September 27, 2011) - Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the endomicroscopy market, today announced a corporate partnership with the American Society for Gastrointestinal Endoscopy (ASGE). The collaboration demonstrates Mauna Kea Technologies' commitment to help the ASGE achieve its mission to advance patient care and digestive health by promoting excellence and innovation in endoscopy.

"Support from corporate partners such as Mauna Kea Technologies helps us expand the understanding and practical application of medical innovations that improve our ability to diagnose and treat patients," said ASGE President Gregory G. Ginsberg, MD, FASGE. "We look forward to working together with Mauna Kea as a long-term partner to deliver on our society's goal of improving GI health."

The ASGE advances patient care by supporting research and moving it quickly into practice; keeping practitioners on the cutting edge through specialized education and training; and raising awareness and understanding of GI endoscopy-related health issues through public outreach initiatives. The ASGE also helps patients find qualified endoscopists.

"Mauna Kea Technologies is dedicated to working closely with ASGE to support education, training and adoption of innovative technologies including Cellvizio®," said Sacha Loiseau, founder and CEO, Mauna Kea Technologies. "We have dedicated ourselves to developing and rigorously evaluating advanced endoscopy tools that provide physicians with more real-time visual information than they've ever had before. We are proud to be a corporate partner with the ASGE due to its tireless efforts to move the field of endoscopy forward. We also applaud the ASGE's efforts to offer gastroenterologists access to training with the latest technologies that have the potential to change the way GI disease is detected and treated. We look forward to a long-term relationship with the society."

About the ASGE Foundation GI Corporate Partners Program
The ASGE Foundation is the philanthropic arm of the American Society for Gastrointestinal Endoscopy. Its mission is to provide long-term financial support for ASGE by raising funds and building endowments through charitable gifts and contributions. Through unrestricted contributions to the ASGE Foundation, GI Corporate Partners demonstrate their shared commitment to partner in ASGE's mission to advance patient care and digestive health by promoting excellence and innovation in endoscopy.

About the American Society for Gastrointestinal Endoscopy
Since its founding in 1941, the American Society for Gastrointestinal Endoscopy (ASGE) has been dedicated to advancing patient care and digestive health by promoting excellence in gastrointestinal endoscopy. ASGE, with nearly 12,000 members worldwide, promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit www.asge.org and www.screen4coloncancer.org for more information and to find a qualified doctor in your area.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies visit www.maunakeatech.com

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Mauna Kea Technologies ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marches financiers ("AMF") granted its visa number 11-236 on June 20, 2011, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.